Review

Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches

Kamya Sankar 1, Sunitha Nagrath 2,3,† and Nithya Ramnath 4,*,†

1 Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-5848, USA; ksankar@med.umich.edu
2 Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109-5848, USA; snagrath@umich.edu
3 Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109-5848, USA
4 Division of Medical Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI 48109-5848, USA
* Correspondence: nithyar@umich.edu
† Equal contribution: S.N. and N.R.

Simple Summary: Non-small cell lung cancer is the most common type of lung cancer. Anaplastic Lymphoma Kinase (ALK) rearrangements have been found in 5–6% of non-small cell lung cancers. While ALK rearranged non-small cell lung cancer is exquisitely sensitive to ALK directed targeted therapies, it is generally resistant to immune-based therapies. We aim to describe the mechanisms by which ALK-rearranged non-small cell lung cancers escape host immunity and are thereby unresponsive to immunotherapies. Furthermore, we describe new immunotherapy strategies and the promises and challenges in incorporating these into clinical practice.

Abstract: Rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene have been implicated in 5–6% of all non-small cell lung cancers. ALK-rearranged non-small cell lung cancers are sensitive to ALK-directed tyrosine kinase inhibitors, but generally resistant to single-agent immune checkpoint inhibitors. Here, we aim to describe the mechanisms of ALK aberrations in non-small cell lung cancer by which an immunosuppressed tumor microenvironment is created, leading to host immune evasion. We report pre-clinical and clinical studies evaluating novel immunotherapeutic approaches and describe the promises and challenges of incorporating immune-based treatments for ALK-rearranged non-small cell lung cancer.

Keywords: ALK; ALK-rearrangements; non-small cell lung cancer; tyrosine kinase inhibitors; immune evasion; immunotherapy; cancer vaccine

1. Introduction

Non-small cell lung cancer (NSCLC) accounts for 80% of lung cancers and is one of the leading causes of cancer-related mortality worldwide [1,2]. In 2007, NSCLC tumors harboring mutations in the anaplastic lymphoma kinase (ALK) gene were identified [3]. ALK rearrangements result in an oncogenic driver in 5–6% of NSCLC cases [4], representing approximately 100,000 new cases of lung cancer annually worldwide. Patients with ALK-rearranged NSCLC are characterized by an absence of smoking or light smoking history and a younger age at diagnosis (median age at diagnosis: 54 years) [5].

1.1. ALK Oncogene

The ALK gene encodes a tyrosine kinase receptor which shares a high level of similarity with the insulin receptor but has a unique glycine-rich extracellular domain. The intracellular domain of the ALK protein shares 80% homology with leukocyte tyrosine kinase (LTK), which has been implicated in immune-related and inflammatory diseases.
The human ALK/LTK family is activated by small peptide ligands, FAM150A(AUGβ) and FAM150B(AUGα) [6,7]. The physiologic role of wildtype ALK is yet to be understood completely, but tissue expression has been found to be restricted to the peripheral and central nervous systems [8]. These are considered to be “immune-privileged sites”, i.e., sites with sufficient immune tolerance to self-antigens [9]. Thus, the ALK protein may represent a potential antigen for the human immune system [10,11].

ALK was first discovered to play a role in oncogenesis in 1994 when the NPM-ALK fusion was identified in anaplastic large-cell non-Hodgkin’s lymphoma (ALCL) [12]. Since then, fusions, mutations, and alternative splicing of ALK has been detected in several cancers including NSCLC, renal cell carcinoma, thyroid cancer, digestive tract cancer, breast cancer, ovarian carcinoma and leukemia [13–15]. The EML4-ALK fusion was first observed in five out of 75 (6.7%) Japanese patients with lung cancer, occurring mutually exclusive of other driver mutations such as EGFR or KRAS [3]. EML4-ALK translocation results in constitutive ALK tyrosine kinase activity, representing an oncogenic addiction pathway in lung cancer. The frequency of EML4-ALK fusion in NSCLC has ranged from 2% to 7% in several studies, with an average frequency of ~5% [16,17]. Moreover, 19 other fusion partners have been identified in ALK-rearranged NSCLC including KIF5B, TGF, TPR, and KLC1 [18,19].

1.2. Models and Techniques to Study ALK-Rearranged NSCLC In Vivo

The EML4-ALK fusion gene was first identified in a mouse model in which inversion within chromosome 2p resulted in an EML4-ALK fusion gene. Forced expression of EML4-ALK in mouse 3T3 fibroblasts resulted in subcutaneous tumors in nude mice [3], while oral administration of an ALK-directed tyrosine kinase inhibitor (TKI) resulted in rapid tumor regression [20]. However, drug screening and modeling for EML4-ALK positive NSCLC cells in vitro and in vivo mouse models has been challenging. Newer models have used viral-mediated delivery of the CRISPR/cas9 system to somatic cells of adult animals to induce chromosomal rearrangements. A CRISPR/cas9 adeno viral vector was used to generate a mouse model of EML4-ALK positive lung cancer [21]. These tumors displayed typical molecular features of ALK-rearranged human NSCLC and responded to treatment with ALK TKI. Similarly, a CRISPR/cas9 lentiviral vector was used to generate EML4-ALK positive lung cancers in mice models via intratracheal or intrapulmonary inoculation [22]. The CRISPR/cas9 system provides unique opportunities to test the efficacy of targeted therapies, investigate mechanisms of drug resistance, and to test newer immune-based therapeutic strategies for ALK rearranged lung cancer in preclinical in vivo models.

1.3. Targeted Therapy for ALK-Rearranged NSCLC

Targeted therapies with small-molecule TKIs have revolutionized the prognosis and management of oncogene-addicted NSCLC. Crizotinib, a multi-targeted TKI with activity against MET, ALK, and ROS1, was the first ALK inhibitor to be approved by the U.S. Food and Drug Administration in 2011 for previously untreated metastatic ALK-rearranged NSCLC, based on results of a single-arm study that demonstrated an objective response rate of 61% [23]. Since then, four additional TKIs have been approved for treatment of advanced ALK-rearranged NSCLC including ceritinib, alectinib, brigatinib, and lorlatinib. Patients with ALK-rearranged NSCLC generally can receive 2–3 ALK TKIs sequentially prior to moving on to a non-targeted systemic treatment at the time of progression.

While targeted therapies have led to significant improvement in the management and prognosis of oncogene-addicted NSCLC, acquired resistance to TKIs is almost always inevitable. Resistance to ALK inhibitors can be mediated by point mutations in the ALK kinase domain, amplifications in the ALK gene or constitutive activation of bypass oncogenic pathways (i.e., EGFR, c-KIT, c-MET, and IGF-R1) [24–26]. Further understanding of bypass resistance mechanisms to ALK inhibitors and exploration of other therapeutic strategies, for example with immune-based or combination approaches, is required to prolong duration of treatment response and offer additional treatment options.
1.4. The Current Landscape of Immunotherapeutic Approaches for Treatment of ALK-Rearranged NSCLC

Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and CTLA-4 are promising tools against NSCLC. However, these therapies are less effective in those harboring oncogenic driver mutations, such as EGFR or ALK. Pre-clinical and clinical studies have demonstrated the up-regulation of immune checkpoints such as PD-L1 in de novo EGFR-mutant and ALK-rearranged tumors [27–30] leading to the question of whether ICI alone or in combination with targeted TKI would offer clinical benefit in ALK-altered NSCLC. However, randomized controlled trials evaluating ICI in NSCLC either have not included patients with ALK-rearrangements or have not had sufficient numbers of patients to provide meaningful subgroup analysis [31–34]. Retrospective studies from a global multicenter network of patients and a national database of U.S. oncology practices have reported patients with ALK-rearranged NSCLC tumors to be relatively refractory to single-agent ICI therapy (median progression-free survival of ~2–3 months) [11,35], indicating that the clinical benefit of ICI in ALK-rearranged NSCLC is modest to poor. Herein, we aim to discuss the immune biology of ALK-rearranged NSCLC, mechanisms which lead to immune resistance, and existing pre-clinical and clinical data regarding immunotherapeutic approaches for treatment of ALK-rearranged NSCLC which may inform novel treatment strategies in the future.

2. Tumor Microenvironment of ALK-Rearranged NSCLC

2.1. The Immunosuppressive Microenvironment in ALK-Rearranged NSCLC

PD-L1 expression is one of the primary immunosuppressive drivers in many cancers, but immune evasion is facilitated by various cells of the immune system [36]. In 2004, the concept of immmunoediting was described to explain the relationship between the tumor and its microenvironment, involving an elimination phase, equilibrium phase, and the immune evasion phase [37] (Figure 1: Tumor microenvironment in NSCLC with wild type ALK).

![Figure 1](image)

Figure 1. Tumor microenvironment in ALK-wildtype non-small cell lung cancer. TGFβ: Transforming Growth Factor β. IL-10: Interleukin 10. TNFα: Tumor necrosis factor alpha. IDO: Indoleamine 2,3-dioxygenase. PGE2: Prostaglandin E2. COX2: Cyclooxygenase 2.

The tumor microenvironment (TME) in ALK-rearranged caners includes interaction of tumor-associated macrophages (TAMs), CD4+ T cells, CD8+ T cells, regulatory T cells (FOXP3+) and mast cells [38]. In ALCL, pre-clinical models have shown a positive correlation between PD-L1 expression in the tumor cells and TAMs in ALK-positive ALCL.
and conversely, a negative correlation in ALK-negative ALCL [39,40]. The ultimate fate of the relationship between PD-L1 expression and FOXP3+ T regulatory cells is to rescind effector CD8+ T cell-mediated tumor response ultimately leading to T cell exhaustion [41]. Furthermore, PD-L1 expression has been shown to play an important role in regulating induced T regulatory cells and sustaining their function [42]. The ratio of CD8+ :FOXP3+ TILs has been shown to be more informative than each being assessed separately, as the ratio more accurately represents the reciprocal interplay between the effector CD8+ TILs and repressive FOXP3+ T regulatory cells in the TME [43].

2.2. Pre-Clinical Studies Evaluating the Role of PD-1/PD-L1 in Immune Evasion of ALK-Rearranged NSCLC

PD-L1 and PD-L2 are commonly overexpressed on tumor cell surfaces [44,45]. Forced expression of PD-L1 on the surface of tumor cells in mice inhibits T-cell mediated antitumoral immune responses via the PD-1/PD-L1 pathway [46,47]. Upregulation of the PD-1 pathway may be mediated by innate and adaptive resistance mechanisms [48]. Constitutive upregulation of PD-L1 is an example of innate resistance, as was shown in ALCL where NPM-ALK induces CD274 (PD-L1) expression by activating transcription factor STAT3. Binding of STAT3 to the CD274 gene promoter in vitro and in vivo was required for PD-L1 gene expression [30]. In contrast, adaptive immune resistance may induce PD-L1 expression in response to local inflammatory signals produced by an active anti-tumor response.

In NSCLC tumors, the EML4-ALK fusion is hypothesized to create an immunosuppressive TME by activation of downstream oncogenic signaling pathways leading to the activation of the PI3K, MAPK, and Hippo pathways [29,49] (Figure 2a). Koh et al. were the first to report the correlation of EML4-ALK and increased PD-L1 expression through regulation of transcription factors in lung adenocarcinoma cells. Moreover, PD-L1 expression was increased by regulating hypoxia-inducible factor-1α and STAT3 activities under hypoxia, but STAT3 alone under normoxia, suggesting a differential regulation of PD-L1 expression depending on normoxia versus hypoxia in the TME [50]. Upon clinicopathological correlation of PD-L1 expression to outcomes in patients with ALK-rearranged NSCLC, PD-L1 expression had no influence on disease-free survival among patients who underwent surgical resection. By contrast, in 90 patients with ALK-rearranged adenocarcinoma who received crizotinib, strong PD-L1 expression was significantly associated with an unfavorable clinical outcome with shorter progression-free survival and overall survival. Importantly, PD-L1 was consistently retained or increased after acquired resistance to crizotinib in a subset of patients. PD-L1 expression is generally downregulated during the efficacious phase of TKI treatment (Figure 2b). Therefore, up-regulation of PD-L1 at time of acquired resistance to TKI may be due to the restoration of ALK in settings of failed ALK inhibition leading to ALK-mediated upregulation of PD-L1 or may represent a PD-1/PD-L1 pathway mediated immune escape mechanism [50].

Upregulation of PD-L1 expression in ALK-rearranged NSCLC was supported by an in vitro study by Hong et al., where cell apoptosis and viability tests were used to study immune suppression by ALK activation and immune reactivation by ALK TKIs and anti-PD-1 antibody in a NSCLC tumor cell and DC-CIK cell co-culture system. Overexpression of ALK fusion protein increased PD-L1 expression, leading to increased apoptosis of T cells. While ALK TKIs directly inhibited tumor viability and enhanced antitumor immunity via downregulation of PD-L1, anti-PD-1 antibody was effective in both crizotinib sensitive and resistant cell lines, suggesting the need for further study in anti-PD-1 blockade for treatment of ALK-rearranged NSCLC [28]. Similar trends were noted by Ma et al. in a study evaluating NSCLC cell lines concurrently with patient samples. PD-L1 expression was higher in cell lines harboring the EML4-ALK fusion gene via expression of downstream pathways such as AKT, ERK, and STAT3, while incubating with crizotinib led to significant downregulation of PD-L1. The activity of crizotinib-sensitive cells was also inhibited by a PD-1 targeted agent and combination of both drugs inhibited cell viability more strongly than with crizotinib alone [51]. These findings were supported by another study evaluating 134 surgically resected NSCLC specimens which found PD-L1 expression by
immunohistochemistry to be higher in the cell lines positive for EML4-ALK compared to those negative for the fusion gene. The forced expression of EML4-ALK markedly increased PD-L1 expression in adenocarcinoma cells. Endogenous expression of PD-L1 in EML4-ALK positive NSCLC was attenuated by treatment with ALK inhibitor alectinib as well as inhibitors of downstream pathways (MEK-ERK and PI3K-AKT) [29]. The aforementioned studies imply a direct link between the constitutive oncogene pathway activation by ALK and upregulation of PD-L1 expression as an adaptive mechanism for immune evasion in ALK-rearranged NSCLC.

2.3. Clinical Studies Correlating PD-L1 Expression and Response to Immune Checkpoint Inhibitors in Patients with ALK-Rearranged NSCLC

Despite preclinical studies correlating ALK-rearrangement with upregulation of PD-L1 expression, clinical studies have not confirmed this. In fact, the opposite has been suggested by retrospective studies where ALK-rearranged NSCLC has correlated with low PD-L1 expression and poor response to ICI. In a retrospective analysis of 58 patients receiving anti-PD-1 ICI for advanced NSCLC, a subset of patients with ALK-rearrangement had low PD-L1 expression, low CD8+ TILs, and low response rates to anti-PD1 blockade [52]. Another study with 715 NSCLC patients had similar findings, where a subset analysis of patients with EGFR or ALK rearrangements had the lowest proportion of PD-L1(+)/CD8+(+) tumors and highest proportion of PD-L1(−)/CD8(−) tumors. Furthermore, patients with PD-L1 positive tumors had the shortest median overall survival [53]. A recent retrospective analysis of East Asians showed similar findings, where patients with EGFR-mutant or ALK-rearranged NSCLC had the highest proportion of PD-L1(−)/CD8(−) tumors. Gene expression profiling of 11 ALK-rearranged NSCLC tumors was performed and showed an immune infiltrating phenotype characterized by a lack of CD8+ T cells or activated memory CD4+ T cells [54].
Upregulation of PD-L1 expression in ALK-rearranged NSCLC as shown in preclinical models has not translated to an improved clinical benefit with ICI. This may be due to multiple factors, including a TME that is characterized by lack of infiltrating CD8+ T cells and complex interplay of constituents such as PD-L1 expressing TAMs and induced FOXP3+ T regulatory cells. Furthermore, ALK-rearranged NSCLC present with fewer non-synonymous mutations compared with smoking associated NSCLC [55], that result in a less inflamed TME as well as less neo-antigen generation, leading to a potentially weaker response to ICI.

3. Immunotherapy Approaches in Treatment of ALK-Rearranged NSCLC

3.1. The Role of PD-1 Axis Checkpoint Inhibitors in ALK-Rearranged NSCLC

The majority of prospective randomized controlled trials evaluating efficacy of ICI in advanced NSCLC have excluded those with ALK-rearrangements or have had insufficient numbers of patients to provide meaningful subgroup analyses.

3.1.1. Retrospective Studies Evaluating ICIs in ALK-Rearranged NSCLC

Retrospective studies have shown lack of efficacy with single-agent ICI in ALK-rearranged NSCLC. In a single institutional retrospective study evaluating patients with NSCLC who were treated with ICI between 2011 and 2016, none of the ALK-positive patients had an objective response, in comparison with an objective response of 23.3% in ALK-negative patients [52]. In another multicenter retrospective analysis, among 23 ALK-rearranged NSCLC patients, none had a confirmed radiographic response while 21% had stable disease and 78% progressed [35]. In a global multicenter cancer registry database, Jahanzeb et al. reported similarly low response rates in 83 patients with ALK-rearranged NSCLC receiving ICI, where median time to discontinuation of ICI was 2.1 months and median progression-free survival was 2.3 months [11]. These findings are summarized in Table 1.

Table 1. Retrospective studies evaluating patients with advanced ALK-rearranged non-small cell lung cancer treated with immune checkpoint inhibitors.

| Study Description | Author/Year | Total No. of Patients | No. of Patients with ALK Rearrangements | Objective Response Rate in ALK Rearranged Patients | Median PFS in ALK-Rearranged Patients |
|-------------------|-------------|-----------------------|----------------------------------------|-----------------------------------------------|-----------------------------------------|
| Single institutional study of EGFR and ALK-mutated NSCLC patients treated with PD-1/PD-L1 inhibitors between 2011–2016 | Gainor 2016 [52] | 28 | 6 (21.4%) | 0% | 2.07 m. (95% CI: 1.87–2.17) |
| Multicenter international study evaluating patients with advanced NSCLC with at least one driver mutation treated with PD-1/PD-L1 inhibitor | Mazieres 2019 [35] | 551 | 23 (4.2%) | 0% | 2.5 m. (95% CI: 1.5–3.7) |
| Multicenter study evaluating patients with ALK-rearranged NSCLC treated with anti PD-1/PD-L1 inhibitors | Jahanzeb 2020 [11] | 83 | 83 (100%) | 3.6% | 2.34 m. (95% CI: 1.55–3.09) |

3.1.2. Prospective Clinical Trials Evaluating ALK-Rearranged NSCLC Patients Treated with ICIs

To our knowledge, the only prospective randomized clinical trials evaluating efficacy of ICIs in NSCLC which have included EGFR-mutant or ALK-rearranged NSCLC patients are the following: CheckMate 057, KEYNOTE-010, POPLAR, and OAK (Table 2). In CheckMate 057, nivolumab was compared to docetaxel in patients with advanced NSCLC who had progressed on doublet chemotherapy. Thereby, 82 of 292 (14%) patients in the nivolumab group and eight of 290 (3%) patients in the docetaxel group were ALK-positive. The EGFR-mutant patients in the nivolumab group had no survival benefit, and responses
in the ALK-rearranged group were not reported due to too few patients [32]. KEYNOTE-010 evaluated the efficacy of pembrolizumab versus docetaxel in previously treated advanced NSCLC patients. Two of 344 patients in the pembrolizumab 2 mg/kg group, four of 346 patients in the pembrolizumab 10 mg/kg group and 2 of 342 patients in the docetaxel group harbored ALK-rearrangements. Similar to CheckMate 057, the EGFR-mutant patients did not have a survival benefit with pembrolizumab, and outcomes for the ALK-positive patients were not reported due to too few patients [33]. In both the POPLAR and OAK trials, though ALK-rearranged patients were allowed, these were only represented in the chemotherapy groups [34]. These findings are summarized in Table 2.

### Table 2. Prospective clinical trials evaluating immune checkpoint inhibitors in advanced non-small cell lung cancer patients which included patients with ALK-rearranged non-small cell lung cancer.

| Trial  | Author/Year   | Total No. of Patients | Treatment                                      | No. of Patients with ALK Rearrangements in Immunotherapy Arm vs. Chemotherapy Arm (%) | Median OS (in the Entire Study Population) * |
|--------|---------------|-----------------------|-----------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------|
| CheckMate 057 | Borghei 2015 [32] | 582                  | Nivolumab vs. docetaxel                        | 13 (4%) vs. 8 (3%)                                                                   | 12.2 vs. 9.4 m.                              |
| Keynote-010 | Herbst 2016 [33] | 1034                 | Pembrolizumab vs. docetaxel                    | 7 (1%) vs. 2 (0.5%)                                                                  | 10.4 vs. 12.7 m.                             |
| POPLAR   | Fehrenbacher 2016 [34] | 287                  | Atezolizumab vs. docetaxel                     | 0 vs. 3 (2%)                                                                         | 12.6 vs. 9.7 m.                              |
| OAK      | Rittmeyer 2017 [34] | 1225                 | Atezolizumab vs. docetaxel                     | 2 (<1%) vs. 0                                                                         | 13.8 vs. 9.6 m.                              |

* Median OS in the ALK-rearranged population was not reported due to too few patients.

### 3.2. The Role of PD-1 Axis Inhibitors in Combination with ALK-directed TKI

Combination strategies of ALK TKI with ICI therapy have been studied and preliminary data has shown activity. However, long-term efficacy outcomes are yet to be reported and toxicity rates are non-trivial. CheckMate 370 was a phase I/II study of the combination of nivolumab plus crizotinib in previously untreated advanced ALK-rearranged NSCLC. Of the first 13 patients treated, five (38%) developed severe hepatic toxicity leading to discontinuation of the treatment, and two (15%) died of treatment-related adverse effect leading to discontinuation of patient enrollment [56]. In another phase IB dose-escalation trial of 36 previously treated or TKI-naïve ALK-rearranged NSCLC patients, nivolumab 3 mg/kg every two weeks was evaluated in combination with ceritinib given 450 mg/day or 300 mg/day. Among TKI-naïve patients, the objective response rate was 83% in the ceritinib 450 mg/day cohort versus 70% in the ceritinib 300 mg/day cohort and PD-L1 positivity correlated with higher response rates. However, frequent grade 3 or 4 adverse events including increases in liver function enzymes, rash and diarrhea, required protocol modification to address toxicities and ultimately enrollment discontinuation [57]. JAVELIN 101 is a phase IB/II clinical trial evaluating previously treated ALK-rearranged NSCLC patients with either avelumab plus lorlatinib or avelumab plus crizotinib. Preliminary data showed objective response rate of avelumab plus lorlatinib of 46.7% versus avelumab plus crizotinib of 16.7%, along with an acceptable safety profile in the avelumab plus lorlatinib group [58] (NCT02584634). Ipilimumab, a CTLA4 inhibitor, was also studied in combination with erlotinib or crizotinib for EGFR-mutated or ALK-rearranged NSCLC patients in a phase I trial, where a median of four doses of ipilimumab were given to the entire cohort. Of three ALK-rearranged patients, one developed hypophysitis requiring treatment discontinuation and one developed grade 2 pneumonitis, with a median PFS reported of 24.1 months. Other studies evaluating similar combination strategies have been reviewed elsewhere [59] though still require long term outcomes data to assess safety and efficacy. The trials involving ALK TKI with ICI have not yet been evaluated in a randomized phase II or III clinical trial. However, the preceding data suggest that this combination strategy in general has a poor therapeutic ratio with modest benefit and a high toxicity profile.
3.3. Adoptive T cell Approaches in Treatment of ALK-Rearranged NSCLC

Though chimeric antigen receptor (CAR) T cell therapy has been effective in treatment of hematologic malignancies, treating solid tumors using CAR-T cell therapy remains a significant challenge. A pilot study using anti-MUC1 CAR-T cells with PD-1 knockout to treat advanced NSCLC patients showed an objective response in two out of six evaluable patients though the therapeutic benefit was variable in each patient. A phase I study (NCT03330834) evaluating PD-L1 CAR-T cells in patients with advanced lung cancer terminated early due to a serious adverse event in the one enrolled participant.

CAR-T approaches are enticing particularly for tumors with immunosuppressed TMEs, such as ALK-rearranged NSCLC, however, there are several challenges to overcome including improvement in the CAR structure, identification of specific tumor antigens to target, overcoming complexities of the TME, and accessing/penetrating large volume solid tumors for effective treatment [60]. CAR-based immunotherapy has previously been studied in ALK-positive pediatric solid tumors. An ALK-directed CAR incorporating the single-chain variable fragment sequence of the ALK48 monoclonal antibody produced a local cytokine-mediated inflammatory response and demonstrated cytotoxic activity of ALK-expressing tumor cells in vitro but had finite anti-tumor activity in xenograft models of neuroblastoma [61]. CAR-T induced anti-tumor activity was found to be highly dependent on the density of target antigens and CAR density on T cells.

Recently, adoptive cell therapy, a technique that utilizes ex vivo expanded T lymphocytes to increase the effector cell pool in tumors, has been suggested as a therapeutic approach in NSCLC. NSCLC has one of the highest clonal mutational burdens, providing rationale to develop clonal neoantigen reactive T cells (cNeT) for this indication [62]. Robertson et al. described a method in which autologous TILs are isolated from a sample of the patient’s tumor and clonal neoantigens are identified by whole exome and RNA sequencing. Dendritic cells are then loaded with patient-specific clonal neoantigens and cultured with TILs, producing ATL001. ATL001 is therefore derived from autologous TILs designed to target patient-specific neoantigens which are specific to tumor cells and may be absent in healthy tissue. ATL001 is being evaluated in patients with advanced NSCLC (NCT04032847) [63].

3.4. Cancer Vaccine Therapy in Advanced ALK-Rearranged NSCLC

The concept of vaccines for treatment of cancers is to stimulate antigen-specific immune response by presenting a tumor associated antigen (TAA) [64]. Vaccines have been used for both prevention and treatment of cancer. Relevant examples include the recombinant human papillomavirus vaccine [65] and an immunogenic personalized neoantigen vaccine (derived from TAA) for patients with melanoma [66]. For NSCLC, two vaccines are approved in other countries. The CIMAavax Epidermal Growth Factor (EGF) vaccine is a chemical conjugate of the Epidermal Growth Factor with the P64 protein from Meningitis B bacteria. The CIMAavax EGF is approved in Cuba, Peru, and Venezuela for stage III and IV NSCLC after progression on first line therapy based on results from a phase II randomized controlled study showing safety and efficacy when compared to best supportive care [67]. Patients with advanced NSCLC were randomized to EGF vaccinations or best supportive care after progression on first-line chemotherapy. A good antibody response, representative of immunogenicity of the vaccine, was detected in 51.4% of vaccinated patients. While the vaccinated group had a trend towards improved survival (median OS 12.7 vs. 8.5 months), these differences were not statistically significant. This vaccine has not yet been approved in other countries though trials are ongoing in the United States, Europe, and Japan. Racotumomab is a murine IgG1 antibody directed against NeuGcGM3 ganglioside, a tumor antigen expressed in NSCLC, and is approved in Argentina and Cuba for advanced NSCLC after progression on first line therapy [64]. This was based on a randomized placebo-controlled multicenter trial which randomized patients to racotumomab or placebo maintenance if patients had stable disease after first-line chemotherapy. The median PFS and OS was improved in the racotumomab arm with statistical significance.
Racotumomab has yet to be evaluated in the United States or Europe [68]. In the United States, though several types of vaccines (allogenic, peptide, autologous, DNA, and vector-based) have demonstrated safety and good tolerability in advanced NSCLC, the clinical benefit defined in response rates and survival outcomes have been poor in clinical trials. Combination approaches are now being evaluated including vaccine in combination with ICI, vaccine in combination with chemotherapy, and vaccine in combination with ICI and chemotherapy. These include a phase I/II clinical trial with CIMAvax-EGF in combination with nivolumab or pembrolizumab (NCT02955290) (currently recruiting), a phase I/II trial testing Adenovirus Expressing MAGE-A3 and MG1-MAGEA3 in combination with pembrolizumab (NCT02879760) (closed; data yet to be reported) and a phase II trial evaluating combination of TG4010 with nivolumab (NCT02823990) (study terminated due to low enrollment).

In ALK-rearranged NSCLC, one strategy to convert the immunosuppressed TME to an immune-responsive TME is by use of an ALK-directed vaccine, in order to stimulate TILs into the TME [10]. ALK has been shown to be antigenic in human lymphomas, with demonstration of spontaneous B and T cell responses against the ALK protein by measurable antibodies, CD8+ cytotoxic T cells and CD4+ helper T cells directed against ALK epitopes [69,70]. Furthermore, tissue expression of ALK in humans is largely restricted to the central and peripheral nervous systems [8]. Due to minimal systemic exposure to ALK throughout human development, the ALK protein has many features of an ideal tumor antigen to elicit a vaccine response against. Voena et al. developed an ALK vaccine containing a DNA plasmid coding the intracytoplasmic domain of ALK, which was shown to be effective in a mouse model of ALK-positive NSCLC by eliciting a tumor-specific cytotoxic response and preventing tumor growth. In mice models with EML4-ALK NSCLC, the average number of tumors detected in control mice was 58 whereas ALK-vaccinated mice only had 16 at week 20. Survival was extended by 18 weeks in EML4-ALK mice which were vaccinated as compared to control. In examination of the TME, ALK vaccine was shown to increase the number of intratumoral T cells with a higher CD8+ :CD4+ ratio, and higher CD8+ : FOXP3+ ratio. The authors then tested the impact of the PD-1/PD-L1 pathway on the efficacy of the ALK vaccine. In the presence of high PD-L1 expression, the vaccine was less effective, but could be overcome by concurrent treatment with anti-PD-1 antibody [71]. Furthermore, in vaccinated mice, eventual tumor growth led to death, likely due to development of resistance mechanisms and immune evasion. Diminished efficacy over time due to upregulation of immune checkpoints such as PD-L1 could be overcome by concurrent administration of anti-PD-L1 antibodies. Another DNA plasmid peptide vaccine was also shown to be effective in ALK-positive NSCLC mouse models [72]. Though an ALK vaccine for ALK-positive NSCLC has yet to be tested in humans, it is currently positioned for a future phase I clinical trial [73].

4. Conclusions

ALK-rearranged NSCLC comprise 5–6% of all NSCLC and are exquisitely sensitive to ALK-directed TKIs, four of which are now approved for treatment of patients with advanced ALK-rearranged NSCLC. After failure on one or more ALK TKIs, salvage approaches include chemotherapy and/or chemo-immunotherapy combination strategies. Despite pre-clinical studies suggesting up-regulation of PD-L1 in ALK-rearranged NSCLC, single-agent ICI have not shown clinical benefit in retrospective studies in the treatment of ALK-rearranged NSCLC. This is thought to be due to an ALK driven immunosuppressive TME characterized by scarce CD8+ TIL and increased FOXP3+ T regulatory cells [74]. The ENIGMA+ trial, a biorepository of ALK-rearranged NSCLC patients in order to further understand the interactions between the tumor and host immunity, is now open to researchers in this field in order to foster development of effective immune-based treatment approaches for ALK-rearranged NSCLC [75]. We have summarized existing data regarding novel immunotherapeutic strategies which may be considered for ALK-rearranged NSCLC. The data from phase I/II clinical trials evaluating ALK TKI in combination with ICI have
been underwhelming, with a significant toxicity profile and a low therapeutic index. The efficacy of adoptive T cell approaches, including CAR-T cell therapy, are limited by need for identification of specific tumor antigens at sufficient densities and overcoming the complexities of the TME with an appropriate CAR structure. ALK-directed vaccine has shown promising efficacy in preclinical models by converting the immunosuppressed TME into a responsive one with potential of improving efficacy particularly when administered with combination strategies. ALK-directed vaccine in combination with ALK TKI may facilitate tumor cell death and release of tumor neoantigens in order to enhance vaccine-mediated antitumor immune response. An optimal time to administer the ALK vaccine might be immediately following maximal response from first line TKI treatment. Alternatively, ALK-vaccine in combination with anti-PD-1/PD-L1 ICI has shown efficacy in preclinical models by overcoming adaptive mechanisms of tumor immune evasion. Therefore, though clinical trials involving vaccine-based approaches will require high pre-clinical effort, the potential for durable efficacy with combination vaccine strategies warrants further investigation [71]. While ALK TKIs have significantly improved the prognosis of patients with advanced ALK-rearranged NSCLC, these cancers remain incurable. Further investigation in targeting the immunosuppressed TME and anticipated clinical trials evaluating ALK directed vaccines represent the future of improving outcomes for patients with ALK-rearranged NSCLC.

**Author Contributions:** Conceptualization, S.N. and N.R.; methodology, K.S.; data curation, K.S.; writing—original draft preparation, K.S.; writing—reviewing and editing, S.N. and N.R.; supervision, N.R.; project administration, N.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global Cancer Statistics, 2012. *CA Cancer J. Clin.* 2015, 65, 87–108. [CrossRef]
2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2018. *CA Cancer J. Clin.* 2018, 68, 7–30. [CrossRef]
3. Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.I.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; et al. Identification of the Transforming EML4-ALK Fusion Gene in Non-Small-Cell Lung Cancer. *Nature* 2007, 448, 561–566. [CrossRef]
4. Devarakonda, S.; Morgensztern, D.; Govindan, R. Genomic Alterations in Lung Adenocarcinoma. *Lancet Oncol.* 2015, e342–e351. [CrossRef]
5. Shaw, A.T.; Solomon, B. Targeting anaplastic lymphoma kinase in lung cancer. *Clin Cancer Res.* 2011, 17, 2081–2086. [CrossRef]
6. Guan, J.; Umapathy, G.; Yamazaki, Y.; Wolfstetter, G.; Mendoza, P.; Pfeifer, K.; Mohammed, A.; Hugosson, F.; Zhang, H.; Hsu, A.W.; et al. FAM150A and FAM150B Are Activating Ligands for Anaplastic Lymphoma Kinase. *Nature* 2015, 4. [CrossRef]
7. Reshetnyak, A.V.; Murray, P.B.; Shi, X.; Mo, E.S.; Mohanty, J.; Tome, F.; Bai, H.; Gunel, M.; Lax, I.; Schlessinger, J. Augmentor α and β (FAM150) Are Ligands of the Receptor Tyrosine Kinases ALK and LTK: Hierarchy and Specificity of Ligand-Receptor Interactions. *Proc. Natl. Acad. Sci. USA* 2015, 112, 15862–15867. [CrossRef] [PubMed]
8. Iwahara, T.; Fujimoto, J.; Wen, D.; Cupples, R.; Bucay, N.; Arakawa, T.; Mori, S.; Ratzkin, B.; Yamamoto, T. Molecular Characterization of ALK, a Receptor Tyrosine Kinase Expressed Specifically in the Nervous System. *Oncogene* 1997, 14, 439–449. [CrossRef] [PubMed]
9. Forrester, J.V.; Xu, H.; Lambe, T.; Cornall, R. Immune Privilege or Privileged Immunity? *Mucosal Immunol.* 2008, 372–381. [CrossRef] [PubMed]
10. Wang, L.; Lui, V.W.Y. Emerging Roles of ALK in Immunity and Insights for Immunotherapy. *Cancers* 2020, 12, 426. [CrossRef]
11. Jahanzeb, M.; Lin, H.M.; Pan, X.; Yin, Y.; Baumann, P.; Langer, C.J. Immunotherapy Treatment Patterns and Outcomes among ALK-Positive Patients with Non–Small-Cell Lung Cancer. *Clin. Lung Cancer* 2020, 22, 49–57. [CrossRef]
12. Morris, S.W.; Kirstein, M.N.; Valentine, M.B.; Dittmer, K.G.; Shapiro, D.N.; Saltman, D.L.; Look, A.T. Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin’s Lymphoma. *Science* 1994, 263, 1281–1284. [CrossRef]
13. Cao, Z.; Gao, Q.; Fu, M.; Ni, N.A.N.; Pei, Y.; Ou, W.B. Anaplastic Lymphoma Kinase Fusions: Roles in Cancer and Therapeutic Perspectives (Review). *Oncol. Lett.* 2019, 2020–2030. [CrossRef]
14. Ross, J.S.; Ali, S.M.; Fasan, O.; Block, J.; Pal, S.; Elvin, J.A.; Schrock, A.B.; Suh, J.; Nozad, S.; Kim, S.; et al. ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. *Oncologist* 2017, 22, 1444–1450. [CrossRef]
15. Lin, E.; Li, L.; Guan, Y.; Soriano, R.; Rivers, C.S.; Mohan, S.; Pandita, A.; Tang, J.; Modrusan, Z. Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers. *Mol. Cancer Res.* 2009, 7, 1466–1476. [CrossRef]

16. Koivunen, J.P.; Mermel, C.; Zejnullahu, K.; Murphy, C.; Liššíts, E.; Holmes, A.J.; Choi, H.G.; Kim, J.; Chiang, D.; Thomas, R.; et al. EML4-ALK Fusion Gene and Efficacy of an ALK Inhibitor in Lung Cancer. *Clin. Cancer Res.* 2008, 14, 4275–4283. [CrossRef]

17. Rodig, S.J.; Mino-Kenudson, M.; Dacic, S.; Yeap, B.Y.; Shaw, A.; Barlett, J.A.; Stubbles, H.; Law, K.; Lindeman, N.; Mark, E.; et al. Unique Clinicopathological Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population. *Clin. Cancer Res.* 2009, 15, 5216–5223. [CrossRef] [PubMed]

18. Rikova, K.; Guo, A.; Zeng, Q.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y.; et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer. *Cell 2007*, 131, 1190–1203. [CrossRef]

19. Togashi, Y.; Soda, M.; Sakata, S.; Sugawara, E.; Hatano, S.; Asaka, R.; Nakajima, T.; Mano, H.; Takeuchi, K. KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only. *PloS ONE* 2012, 7, e31323. [CrossRef] [PubMed]

20. Soda, M.; Takada, S.; Takeuchi, K.; Young, L.C.; Enomoto, M.; Ueno, T.; Haruta, H.; Hamada, T.; Yamashita, Y.; Ishikawa, Y.; et al. A Mouse Model for EML4-ALK-Positive Lung Cancer. *Proc. Natl. Acad. Sci. USA* 2008, 105, 19893–19897. [CrossRef] [PubMed]

21. Maddalo, D.; Manchado, E.; Concepcion, C.P.; Bonetti, C.; Vidigal, J.A.; Han, Y.C.; Ogrodowski, P.; Crippa, A.; Rekhtman, N.; De Stanchina, E.; et al. In Vivo Engineering of Oncogenic Chromosomal Rearrangements with the CRISPR/Cas9 System. *Nature 2014*, 516, 423–428. [CrossRef]

22. Blasco, R.B.; Karaca, E.; Ambrogio, C.; Cheongg, T.C.; Karayol, E.; Minero, V.G.; Voena, C.; Chiarle, R. Simple and Rapid In Vivo Generation of Chromosomal Rearrangements Using CRISPR/Cas9 Technology. *Cell Rep.* 2014, 9, 1219–1227. [CrossRef]

23. Malik, S.M.; Maher, V.E.; Bijvaard, K.E.; Becker, R.L.; Zhang, L.; Tang, S.W.; Song, P.; Liu, Q.; Marathe, A.; Gehrke, B.; et al. U.S. Food and Drug Administration Food Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive. *Clin. Cancer Res.* 2014, 20, 2029–2034. [CrossRef] [PubMed]

24. Choi, Y.L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H.; et al. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. *N. Engl. J. Med.* 2010, 363, 1734–1739. [CrossRef] [PubMed]

25. Katayama, R.; Shaw, A.T.; Khan, T.M.; Mino-Kenudson, M.; Solomon, B.J.; Halmos, B.; Jessop, N.A.; Thomas, C.A.; Barlesi, F.; et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. *N. Engl. J. Med.* 2018, 378, 2288–2301. [CrossRef] [PubMed]

26. Doeeble, R.C.; Pilling, A.B.; Aisner, D.L.; Kutateladze, T.G.; Le, A.T.; Weickhardt, A.J.; Kondo, K.L.; Linderman, D.J.; Heasley, L.E.; Franklin, W.A.; et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2012, 18, 1472–1482. [CrossRef]

27. Chen, N.; Fang, W.; Zhan, J.; Hong, S.; Tang, Y.; Kang, S.; Zhang, Y.; He, X.; Zhou, T.; Qin, T.; et al. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. *J. Thorac. Oncol.* 2015, 10, 910–923. [CrossRef] [PubMed]

28. Hong, S.; Chen, N.; Fang, W.; Zhan, J.; Liu, Q.; Kang, S.; He, X.; Liu, L.; Zhou, T.; Huang, J.; et al. Upregulation of PD-L1 by EML4-ALK Fusion Protein Mediates the Immune Escape in ALK Positive NSCLC: Implication for Optional Anti-PD-1/PD-L1 Immune Therapy for ALK-TKIs Sensitive and Resistant NSCLC Patients. *Oncotechnology 2016*, 5. [CrossRef] [PubMed]

29. Ota, K.; Azuma, K.; Kawahara, A.; Hattori, S.; Iwama, E.; Tanizaki, J.; Harada, T.; Matsumoto, K.; Crippa, A.; Rekhtman, N.; De Stanchina, E.; et al. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and down Stream Signaling Pathways in Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2015, 21, 4014–4021. [CrossRef] [PubMed]

30. Marzec, M.; Zhang, Q.; Goradia, A.; Raghunath, P.N.; Liu, X.; Paessler, M.; Hong, Y.W.; Wysocka, M.; Cheng, M.; Ruggeri, B.A.; et al. Oncogenic Kinase NPM/ALK Induces through STAT3 Expression of Immunosuppressive Protein CD274 (PD-L1, B7-H1). *Proc. Natl. Acad. Sci. USA* 2008, 105, 20852–20857. [CrossRef]

31. Socsinski, M.A.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Mogami, N.; Rodriguez-Arreu, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; et al. Atezolizumab for First-Line Treatment of Metastatic NonQnosquamous NSCLC. *N. Engl. J. Med.* 2018, 378, 2288–2301. [CrossRef] [PubMed]

32. Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced NonQnosquamous Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* 2015, 373, 1627–1639. [CrossRef]

33. Herbst, R.S.; Baas, P.; Kim, D.W.; Felip, E.; Pérez-Gracia, J.L.; Han, J.Y.; Molina, J.; Kim, J.H.; Arvis, C.D.; Ahn, M.J.; et al. Pembroliuzumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. *Lancet 2016*, 387, 1540–1550. [CrossRef]

34. Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; et al. Atezolizumab versus Docetaxel for Patients with Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial. *Lancet 2016*, 387, 1837–1846. [CrossRef]

35. Mazieres, J.; Drilon, A.; Lusque, A.; Mhanna, L.; Cortot, A.B.; Mezquita, L.; Thai, A.A.; Mascaux, C.; Couraud, S.; Veillon, R.; et al. Immune Checkpoint Inhibitors for Patients with Advanced Lung Cancer and Oncogenic Driver Alterations: Results from the IMMUNOTARGET Registry. *Ann. Oncol.* 2019, 30, 1321–1328. [CrossRef] [PubMed]
36. Kim, J.M.; Chen, D.S. Immune Escape to PD-L1/PD-1 Blockade: Seven Steps to Success (or Failure). *Ann. Oncol.* **2016**, *1492–1504*. [CrossRef]
37. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The Three Es of Cancer Immunomodulation. *Annu. Rev. Immunol.* **2004**, *329–360*. [CrossRef]
38. Whiteside, T.L. The Tumor Microenvironment and Its Role in Promoting Tumor Growth. *Oncogene* **2008**, *5904–5912*. [CrossRef]
39. Andorsky, D.J.; Yamada, R.E.; Said, J.; Pinkus, G.S.; Bettle, D.J.; Timmerman, J.M. Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells. *Clin. Cancer Res.* **2011**, *17*, 4232–4244. [CrossRef]
40. Gravelle, P.; Burroni, B.; Péricart, S.; Rossi, C.; Bezombes, C.; Tosolini, M.; Damotte, D.; Brousset, P.; Fournié, J.J.; Laurent, C. Mechanisms of PD-1/PD-L1 Expression and Prognostic Relevance in Non-Hodgkin Lymphoma: A Summary of Immunohistochemical Studies. *Oncotarget* **2017**, *44960–44975*. [CrossRef]
41. Pauken, K.E.; Wherry, E.J. Overcoming T Cell Exhaustion in Infection and Cancer. *Trends Immunol.* **2015**, *265–276*. [CrossRef]
42. Francisco, L.M.; Salinas, V.H.; Brown, K.E.; Vanguri, V.K.; Freeman, G.J.; Kuchroo, V.K.; Sharpe, A.H. PD-L1 Regulates the Development, Maintenance, and Function of Induced Regulatory T Cells. *J. Exp. Med.* **2009**, *206*, 3015–3029. [CrossRef]
43. Roychoudhuri, R.; El, R.L.; Restifo, N.P. The Interplay of Effector and Regulatory T Cells in Cancer. *Curr. Opin. Immunol.* **2015**, *101–111*. [CrossRef] [PubMed]
44. Sfanos, K.S.; Bruno, T.C.; Meeker, A.K.; De Marzo, A.M.; Isaacs, W.B.; Drake, C.G. Human Prostate-Infiltrating CD8+ T Lymphocytes Are Oligoclonal and PD-1+. *Prostate* **2009**, *69*, 1694–1703. [CrossRef] [PubMed]
45. Ahmadzadeh, M.; Johnson, L.A.; Heemskerk, B.; Wunderlich, J.R.; Dudley, M.E.; White, D.E.; Rosenberg, S.A. Tumor Antigen-Specific CD8 T Cells Infiltrating the Tumor Express High Levels of PD-1 and Are Functionally Impaired. *Blood* **2009**, *114*, 1537–1544. [CrossRef]
46. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K.; et al. Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. *Nat. Med.* **2002**, *8*, 793–800. [CrossRef]
47. Taube, J.M.; Anders, R.A.; Young, G.D.; Xu, H.; Sharma, R.; McMillner, T.L.; Chen, S.; Klein, A.P.; Pardoll, D.M.; Topalian, S.L.; et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. *Sci. Transl. Med.* **2012**, *4*. [CrossRef] [PubMed]
48. Pardoll, D.M. The Blockade of Immune Checkpoints in Cancer Immunotherapy. *Nat. Rev. Cancer* **2012**. [CrossRef]
49. Nouri, K.; Azad, T.; Lightbody, E.; Khanal, P.; Nicol, C.J.; Yang, X. A Kinome-Wide Screen Using a NanoLuc LATS Luminescent Biosensor Identifies ALK as a Novel Regulator of the Hippo Pathway in Tumorigenesis and Immune Evasion. *FASEB J.* **2019**, *33*, 12487–12499. [CrossRef]
50. Koh, J.; Jang, J.Y.; Keam, B.; Kim, S.; Kim, M.Y.; Go, H.; Kim, T.M.; Kim, D.W.; Kim, C.W.; Jeon, Y.K.; et al. EML4-ALK in Combination with Crizotinib or Lorlatinib in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). *Ther. Adv. Med Oncol.* **2020**, 36. [CrossRef]
51. Ma, L.; Lv, J.; Dong, Y.; Zhang, X.; Li, X.; Zhang, H.; Nong, J.; Zhang, Q.; Qin, N.; Yang, X.; et al. PD-L1 Expression and CD8+ T Cells Infiltration in Patients with EGFR-Mutated and ALK Rearranged Lung Cancer. *Clin. Cancer Res.* **2020**, 36. [CrossRef]
52. Gainor, J.F.; Shaw, A.T.; Sequist, L.V.; Fu, X.; Azzoli, C.G.; Piotrowska, Z.; Huynh, T.G.; Zhao, L.; Fulton, L.; Schultz, K.R.; et al. Lung Cancer Therapy: Clinical EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. *Clin. Cancer Res.* **2016**, *22*. [CrossRef]
53. Liu, S.Y.; Dong, Z.Y.; Wu, S.P.; Xie, Z.; Yan, L.X.; Li, Y.F.; Yan, H.H.; Su, J.; Yang, J.J.; Zhou, Q.; et al. Clinical Relevance of PD-L1 Expression in Pulmonary Adenocarcinoma via Hypoxia-Inducible Factor (HIF)-1α and STAT3. *Oncotarget* **2016**, *5*. [CrossRef]
54. Jin, R.; Liu, C.; Zheng, S.; Wang, X.; Feng, X.; Li, H.; Sun, N.; He, J. Molecular Heterogeneity of Anti-PD-1/PD-L1 Immunotherapy Efficacy Is Correlated with Tumor Microenvironment in East Asian Patients with Non-Small Cell Lung Cancer. *Cancer Biol. Med.* **2020**. [CrossRef]
55. Govindan, R.; Ding, L.; Griffith, M.; Subramanian, J.; Dees, N.D.; Kanchi, K.L.; Maher, C.A.; Fulton, R.; Fulton, L.; Wallis, J.; et al. Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers. *Cell* **2012**, *150*, 1121–1134. [CrossRef]
56. Spigel, D.R.; Reynolds, C.; Waterhouse, D.; Garon, E.B.; Chandler, J.; Babu, S.; Thurners, P.; Spira, A.; Jotte, R.; Zhu, J.; et al. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation—Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370). *J. Thorac. Oncol.* **2018**, *13*, 682–688. [CrossRef] [PubMed]
57. Felip, E.; De Braud, F.G.; Maur, M.; Loong, H.H.F.; Shaw, A.T.; Vansteenkiste, J.F.; John, T.; Liu, G.; Lolkema, M.P.; Scott, J.W.; et al. Ceritinib plus Nivolumab (NIVO) in Patients (Pts) with Anaplastic Lymphoma Kinase Positive (ALK+)-Advanced Non-Small Cell Lung Cancer (NSCLC). *J. Clin. Oncol.* **2017**, *35* (Suppl. 15), 2502. [CrossRef]
58. Shaw, A.T.; Lee, S.H.; Ramalingam, S.S.; Bauer, T.M.; Boyer, M.J.; Carcereny Costa, E.; Felip, E.; Han, J.-Y.; Hida, T.; Hughes, B.G.M.; et al. Avelumab (Anti-PD-L1) in Combination with Crizotinib or Lorlatinib in Patients with Previously Treated Advanced NSCLC: Phase 1b Results from JAVELIN Lung 101. *J. Clin. Oncol.* **2018**, *36* (Suppl. 15), 9008. [CrossRef]
59. Moya-Horno, I.; Viteri, S.; Karachaliou, N.; Rosell, R. Combination of Immunotherapy with Targeted Therapies in Advanced Non-Small Cell Lung Cancer (NSCLC). *Ther. Adv. Med Oncol.* **2018**. [CrossRef]
60. Zhong, S.; Cui, Y.; Liu, Q.; Chen, S. CAR-T Cell Therapy for Lung Cancer: A Promising but Challenging Future. J. Thorac. Dis. 2020, 4516–4521. [CrossRef]

61. Walker, A.J.; Majzner, R.G.; Zhang, L.; Wanhainen, K.; Long, A.H.; Nguyen, S.M.; Lopomo, P.; Vigny, M.; Fry, T.J.; Orentas, R.J.; et al. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. Mol. Ther. 2017, 25, 2189–2201. [CrossRef]

62. Robertson, J.; Salm, M.; Dang, J. Adaptive Cell Therapy with Tumour-Infiltrating Lymphocytes: The Emerging Importance of Clonal Neoantigen Targets for next-Generation Products in Non-Small Cell Lung Cancer. Immuno-Oncol. Technol. 2019. [CrossRef]

63. Charoentong, P.; Finotto, F.; Angelova, M.; Mayer, C.; Efremova, M.; Rieder, D.; Hackl, H.; Trajanoski, Z. Pan-Cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017, 18, 248–262. [CrossRef]

64. Oliveres, H.; Caglevic, C.; Passiglia, F.; Taverna, S.; Smits, E.; Rolfo, C. Vaccine and Immune Cell Therapy in Non-Small Cell Lung Cancer. J. Thorac. Dis. 2018, S1602–S1614. [CrossRef]

65. Nicol, A.F.; De Andrade, C.V.; Russomano, F.B.; Rodrigues, L.S.; Oliveira, N.S.; Provance, D.W.; Nuovo, G.J. HPV Vaccines: Their Pathology-Based Discovery, Benefits, and Adverse Effects. Ann. Diagn. Pathol. 2015, 418–422. [CrossRef] [PubMed]

66. Ott, P.A.; Hu, Z.; Keskin, D.B.; Shukla, S.A.; Sun, J.; Bozym, D.J.; Zhang, W.; Luoma, A.; Giobbie-Hurder, A.; Peter, L.; et al. An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma. Nature 2017, 547, 217–221. [CrossRef]

67. Gonzalez, G.; Crombet, T.; Torres, F.; Catala, M.; Alfonso, L.; Osorio, M.; Neninger, E.; Garcia, B.; Mulet, A.; Perez, R.; et al. Epidermal Growth Factor-Based Cancer Vaccine for Non-Small-Cell Lung Cancer Therapy. Ann. Oncol. 2003, 14, 461–466. [CrossRef]

68. Alfonso, S.; Valdés-Zayas, A.; Santiesteban, E.R.; Flores, Y.I.; Areces, F.; Hernández, M.; Viada, C.E.; Mendoza, L.C.; Guerra, P.P.; Garcia, E.; et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin. Cancer Res. 2014, 20, 3660–3671. [CrossRef] [PubMed]

69. Passoni, L.; Scardino, A.; Bertazzoli, C.; Gallo, B.; Coluccia, A.M.L.; Lemmonier, F.A.; Kosmatopoulos, K.; Gambacorti-Passerini, C. ALK as a Novel Lymphoma-Associated Tumor Antigen: Identification of 2 HLA-A2.1-Restricted CD8+ T-Cell Epitopes. Blood 2002, 99, 2100–2106. [CrossRef] [PubMed]

70. Ait-Tahar, K.; Cerundolo, V.; Banham, A.H.; Hatton, C.; Blanchard, T.; Kusec, R.; Becker, M.; Smith, G.L.; Pullford, K. B and CTL Responses to the ALK Protein in Patients with ALK-Positive ALC. Int. J. Cancer 2006, 118, 688–695. [CrossRef] [PubMed]

71. Voena, C.; Menotti, M.; Mastini, C.; Giacomoni, F.D.; Longo, D.L.; Castella, B.; Merlo, M.E.B.; Ambrogiolo, C.; Wang, Q.; Minero, G.; et al. Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Res. Artic. Cancer Immunol. Res. 2015, 3. [CrossRef] [PubMed]

72. Blasco, R.B. Abstract A021: Development of an ALK Vaccine to Treat ALK-Rearranged Non-Small Cell Lung Cancers. In Cancer Immunology Research; American Association for Cancer Research (AACR): Philadelphia, PA, USA, 2016; Volume 4. [CrossRef]

73. First Vaccine for Treating ALK-Positive Lung Cancer | LUNGevity Foundation. Available online: https://lungevity.org/news-blogs/blogs/developing-first-vaccine-for-treating-alk-positive-lung-cancer (accessed on 8 January 2021).

74. Liu, S.V.; Camidge, D.R.; Gettinger, S.N.; Giaccone, G.; Heist, R.S.; Hodi, F.S.; Ready, N.E.; Zhang, W.; Wallin, J.; Funke, R.; et al. Long-Term Survival Follow-up of Atezolizumab in Combination with Platinum-Based Doublet Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Eur. J. Cancer 2018, 101, 114–122. [CrossRef] [PubMed]

75. Research Underway to Improve Immunotherapy Outcomes for ALK-Positive Lung Cancer | LUNGevity Foundation. Available online: https://lungevity.org/news-blogs/blogs/research-underway-to-improve-immunotherapy-outcomes-for-alk-positive-lung-cancer (accessed on 15 March 2021).